INSPIRE MEDICAL SYSTEMS INC (INSP)
Sector: Health Care
2026 Annual Meeting Analysis
INSPIRE MEDICAL SYSTEMS INC · Meeting: April 30, 2026
Directors FOR
0
Directors AGAINST
3
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Gary L. Ellis, Georgia Melenikiotou, and Dana G. Mead, Jr. as Class II Directors
Against Analysis
Mr. Ellis has served on the board since 2019, meaning his full tenure overlaps with a period in which Inspire's stock has fallen approximately 79% over three years while the company's own peer group (used as the primary benchmark) fell only about 24% — a gap of 55 percentage points that far exceeds the 20-point threshold our policy requires for a no vote when absolute returns are negative; the five-year check does not rescue this result because the five-year gap of 38 percentage points also exceeds the same 20-point threshold, confirming this is sustained underperformance rather than a temporary dip.
Ms. Melenikiotou has served on the board since 2020, and her tenure substantially overlaps with the period in which Inspire's stock declined roughly 79% while peers fell only about 24%, a 55-percentage-point gap that triggers a no vote under our policy; the five-year gap of 38 points likewise exceeds the 20-point threshold, so the longer track record provides no mitigant, and a no vote is warranted.
Mr. Mead has been a director since 2008, so his tenure fully encompasses the period of severe stock underperformance in which Inspire lost roughly 79% of its value over three years while the company's disclosed peer group declined only about 24%, a 55-percentage-point gap that clearly exceeds the 20-point policy threshold; the five-year picture is equally unfavorable with a 38-point gap above the threshold, confirming sustained rather than temporary underperformance.
For Analysis
All three Class II nominees are voted AGAINST due to sustained, severe stock price underperformance relative to the company's own disclosed compensation peer group: Inspire's three-year total return of approximately -79% trails the peer median of approximately -24% by 55 percentage points, far exceeding the 20-point trigger threshold for companies with negative absolute returns, and the five-year comparison (gap of 38 points) does not provide a mitigating offset under our policy's five-year check.
Say on Pay
✓ FORCEO
Timothy P. Herbert
Total Comp
$7,711,784
Prior Support
93%%
CEO Timothy Herbert received total compensation of approximately $7.7 million for fiscal 2025, which is broadly in line with benchmarks for a CEO at a medical device company of Inspire's size, and the prior say-on-pay vote received 93% support indicating no outstanding shareholder concern requiring remediation; the pay structure is well-designed with approximately 90% of the CEO's target pay being variable and at-risk, including performance stock awards tied to three-year cumulative revenue and operating income goals that actually paid out at only 79% of target reflecting below-target execution, which demonstrates the incentive plan is working as intended. The company has a clawback policy in place, no excise tax gross-ups, and meaningful stock ownership requirements, so the overall program meets the qualitative standards of our policy.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
11 yrs
Audit Fees
$949,280
Non-Audit Fees
$302,514
Ernst & Young has audited Inspire since 2015 (approximately 11 years), well below the 25-year tenure threshold that would raise independence concerns; the non-audit fees (audit-related fees of $43,833 plus tax compliance fees of $69,585 plus other tax services of $189,096 totaling approximately $302,514) represent about 32% of core audit fees of $949,280, comfortably below the 50% threshold that would trigger a no vote; EY is a Big 4 firm appropriate for a $1.6 billion market-cap company, and no material financial restatements were identified.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Approve an Amendment to our Seventh Amended and Restated Certificate of Incorporation to Phase Out the Classified Board Structure and Provide for the Annual Election of All Directors Beginning with our 2029 Annual Meeting of Stockholders
This is a board-proposed charter amendment that would phase out the current classified (staggered) board structure and move to annual elections for all directors starting in 2029, which is a mainstream governance improvement that gives shareholders more frequent accountability over the full board; the change is a direct and concrete response to shareholder feedback gathered in 2025 outreach, satisfying the policy principle that voluntary commitments require a concrete commitment to warrant credit. Under our policy's charter amendment framework, this amendment moves governance in a clearly pro-shareholder direction from the current baseline of staggered three-year terms, and we support it even though the transition is phased rather than immediate, because the improvement from a classified board to annual elections is substantial.
Overall Assessment
The 2026 Inspire Medical Systems annual meeting presents seven proposals; the most significant governance concern is severe and sustained stock price underperformance — Inspire's shares have lost approximately 79% over three years while the company's own disclosed peer group fell only about 24%, a gap that triggers against votes for all three Class II director nominees under our policy, including the founder-CEO Timothy Herbert who serves as both a Class I director (not up for election this year) and as a named executive. On the compensation and governance proposals, the say-on-pay vote passes our screens given a well-structured at-risk pay program and 93% prior-year support, the auditor ratification is straightforward with no independence concerns, and the board-proposed charter amendment to phase out the classified board structure is a genuine governance improvement that merits shareholder support.
Compensation Peer Group
20 companies disclosed in 2026 proxy filing